CN109328197A - 用于治疗具有补体c5多态性的患者的抗c5抗体 - Google Patents

用于治疗具有补体c5多态性的患者的抗c5抗体 Download PDF

Info

Publication number
CN109328197A
CN109328197A CN201780034701.9A CN201780034701A CN109328197A CN 109328197 A CN109328197 A CN 109328197A CN 201780034701 A CN201780034701 A CN 201780034701A CN 109328197 A CN109328197 A CN 109328197A
Authority
CN
China
Prior art keywords
antibody
patient
complement
antigen
polymorphism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780034701.9A
Other languages
English (en)
Chinese (zh)
Inventor
F·穆埃尔斯豪森
M·密尔顿
L·N·A·约翰逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN109328197A publication Critical patent/CN109328197A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780034701.9A 2016-06-07 2017-06-01 用于治疗具有补体c5多态性的患者的抗c5抗体 Pending CN109328197A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346683P 2016-06-07 2016-06-07
US62/346,683 2016-06-07
PCT/IB2017/053245 WO2017212375A1 (en) 2016-06-07 2017-06-01 Anti-c5 antibody for treating patients with complement c5 polymorphism

Publications (1)

Publication Number Publication Date
CN109328197A true CN109328197A (zh) 2019-02-12

Family

ID=59078125

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780034701.9A Pending CN109328197A (zh) 2016-06-07 2017-06-01 用于治疗具有补体c5多态性的患者的抗c5抗体

Country Status (5)

Country Link
US (1) US20190225678A1 (https=)
EP (1) EP3464351A1 (https=)
JP (1) JP2019521105A (https=)
CN (1) CN109328197A (https=)
WO (1) WO2017212375A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
JP7813222B2 (ja) 2019-08-16 2026-02-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度抗ｃ５製剤
JP7798763B2 (ja) * 2019-10-25 2026-01-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ５関連疾患の治療または予防のための投与レジメン
EP4423271A2 (en) 2021-10-28 2024-09-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
CN119409815B (zh) * 2025-01-07 2025-04-08 天辰生物医药(苏州)有限公司 抗人补体c5 vhh抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102170906A (zh) * 2008-08-05 2011-08-31 诺瓦提斯公司 靶定补体蛋白c5的抗体的组合物和方法
WO2014047500A1 (en) * 2012-09-21 2014-03-27 Alexion Pharmaceuticals, Inc. Screening assays for complement component c5 antagonists
CN105143261A (zh) * 2013-01-31 2015-12-09 首尔大学校产学协力团 C5抗体以及用于预防和治疗补体-相关的疾病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
JP2010521194A (ja) * 2007-03-22 2010-06-24 ノバルティス アーゲー Ｃ５抗原およびその使用
LT2894165T (lt) * 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
EP2824111B1 (en) * 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A Antibodies and Methods for Using the Antibodies
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CN107428823B (zh) * 2015-01-22 2021-10-26 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102170906A (zh) * 2008-08-05 2011-08-31 诺瓦提斯公司 靶定补体蛋白c5的抗体的组合物和方法
WO2014047500A1 (en) * 2012-09-21 2014-03-27 Alexion Pharmaceuticals, Inc. Screening assays for complement component c5 antagonists
CN105143261A (zh) * 2013-01-31 2015-12-09 首尔大学校产学协力团 C5抗体以及用于预防和治疗补体-相关的疾病的方法

Also Published As

Publication number Publication date
US20190225678A1 (en) 2019-07-25
JP2019521105A (ja) 2019-07-25
EP3464351A1 (en) 2019-04-10
WO2017212375A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
US11440954B2 (en) Optimized anti-TL1A antibodies
TWI754157B (zh) 抗ｔｉｇｉｔ抗體及其用途
CN109328197A (zh) 用于治疗具有补体c5多态性的患者的抗c5抗体
ES2541142T3 (es) Composiciones y métodos para anticuerpos dirigidos contra la proteína C5 del complemento
ES2431940T3 (es) Anticuerpos contra la ERBB3 y usos de los mismos
WO2019062832A1 (zh) Tigit抗体、其抗原结合片段及医药用途
TW202019480A (zh) 新穎lilrb4抗體及其用途
US20140072577A1 (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
JP7152404B2 (ja) 抗ｌａｉｒ１抗体およびその使用
TW202102546A (zh) 密蛋白抗體及其應用
BRPI0809105A2 (pt) antígenos c5 e uso destes
CN114651013B (zh) 对cd39具有特异性的结合分子及其用途
KR20100067681A (ko) 보체 성분을 조정하기 위한 분자 및 방법
BRPI0619357A2 (pt) anticorpos monoclonais e usos dos mesmos
TW201328706A (zh) 表皮生長因子受體３（ｈｅｒ３）之抗體
US20190315842A1 (en) Inhibitors of complement factor h
KR20230021773A (ko) 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도
TW201328707A (zh) 針對表皮生長因子受體３（ｈｅｒ３）之區域ｉｉ之ｈｅｒ３抗體
US11597778B2 (en) Human monoclonal autoantibodies to ADAMTS13 and uses thereof
JP2023535384A (ja) 抗ｐｄ－１抗体医薬組成物及びその用途
JP2014526886A (ja) マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
TW202140560A (zh) 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途
TW202115125A (zh) 抗ｃｅａ抗體及其應用
WO2025171256A1 (en) Compositions and methods for treating malaria
HK40009967B (zh) 抗lair1抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190212